Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27828990 | 0.88 | GAA (0.46) | POLBKMT2ACA12CA1CA9 | |
| SCHEMBL7682127 | 0.88 | CA12 (0.43) | POLBCA12CA1CA9BRD9 | |
| SCHEMBL15496590 | 0.83 | CA1 (0.39) | POLBKMT2ACA12CA1CA9 | |
| SCHEMBL653538 | 0.82 | CISD2 (0.41) | CA12CA1CA9BRD9LCK | |
| SCHEMBL28797272 | 0.82 | CYP17A1 (0.43) | POLBCA12CA1CA9BRD9 | |
| SCHEMBL12072957 | 0.82 | LCK (0.41) | KMT2ACA12CA1CA9BRD9 | |
| SCHEMBL4568354 | 0.81 | MAPT (0.49) | KMT2ACA12CA1CA9BRD9 | |
| SCHEMBL22743812 | 0.80 | CA12 (0.40) | KMT2ACA12CA1CA9BRD9 | |
| SCHEMBL5477161 | 0.80 | ATR (0.46) | CA12CA1CA9BRD9ALDH1A1 | |
| SCHEMBL15496595 | 0.79 | CA12 (0.36) | KMT2ACA12CA1CA9BRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628666-B1 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-1628666-B1 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2012086735-A1 | CONDENSED HETEROCYCLIC COMPOUND | 大正製薬株式会社 (JP) | 2012-06-28 | — | — | WO | disclosed |
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8017629-B2 | Compounds and uses thereof in modulating amyloid β | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017629-B2 | Compounds and uses thereof in modulating amyloid β | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | NEUROGENETIC PHARMACEUTICALS, INC | 2010-12-30 | — | — | US | disclosed |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | NEUROGENETIC PHARMACEUTICALS, INC | 2010-12-30 | — | — | US | disclosed |
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| CN-1157376-C | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and drugs containing the same | ��һ��������ҩ��ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| EP-1045693-B1 | AMINOPHENOXYACETIC ACID DERIVATIVES AS NEUROPROTECTANTS | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-06-30 | — | — | EP | disclosed |
| US-20040063748-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2003-12-25 | — | — | US | disclosed |
| US-20030139447-A1 | Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2003-07-24 | — | — | US | disclosed |
| US-6559146-B1 | Neuroprotective effects by inducing calbindin D28Kd, one of Ca2+-binding proteins | SUNTORY LIMITED (JP) | 2003-05-06 | — | — | US | disclosed |
| US-6525199-B1 | Ring coupling, reduction and deprotecting; synthesis of compounds for alleviation and treatment of symptoms due to ischemic diseases | SUNTORY LIMITED (JP) | 2003-02-25 | — | — | US | disclosed |
| US-6407099-B1 | SUPPRESSING CYTOTOXIC CALCIUM OVERLOAD AND LIPID PEROXIDATION; ANTIEPILEPTIC, ANTIISCHEMIC, AND ANTIEDEMIC AGENTS; BRAIN, NERVOUS SYSTEM, AND CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1138678-A2 | Process for making N-((4-phenyl) methylphenyl) piperazines | SUNTORY LIMITED (JP) | 2001-10-04 | — | — | EP | disclosed |
| CN-1246110-A | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and drugs containing the same | SUNTORY LTD (JP) | 2000-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | APP, BACE1, BACE2 | POLB 3219/4885KMT2A 3770/4885CA12 2005/4885 |
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | NR1H2, NR1H3, APOL1 | POLB 3468/4885KMT2A 4002/4885CA12 4531/4885 |
| US-20030139447-A1 | Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof | SCN10A, CAMK2A, CAMK2B | POLB 4526/4885KMT2A 2191/4885CA12 1361/4885 |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | HYPK, APP, NEFM | POLB 4051/4885KMT2A 2363/4885CA12 4113/4885 |
| US-20040063748-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | FABP7, SLC1A2, CAMK2A | POLB 4059/4885KMT2A 2239/4885CA12 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.